RespireRx Pharmaceuticals Inc (RSPI)

[neuroinv]

Depends on how much DD they did on CX-1739 when they reviewed CX-717. Since another molecule was inevitably going to go with CX717 (unless they did a very narrow acute-use hospital deal for RD, and that didnt happen), I suspect that they did. Which covers a lot of the ground necessary for term sheets once SA data is in. That is, of course, if the SA trial gives a positive signal.

The competition angle is important if: 1) they think Cortex's molecules are better than their's. Lilly used to not think that, but they've had two or three generations of high-impacts vaporize due to side effects and/or if they are interested in the respiration use patents. The other use patents have little left, so they aren't the competitive draw we once thought they would be.

NeuroInvestment